Get to know our clinical trials
Clinical trial to compare daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autoleukel ciltacabtagene vs. daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autologous stem cell transplantation (ASCT)
THE MAIN OBJECTIVE OF THIS STUDY IS TO EVALUATE THE EFFICACY OF CILTACABTAGENE AUTOLEUCEL (CILTACEL) COMPARED TO STANDARD TREATMENT WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT).
Technical Summary
- RANDOMIZED PHASE 3 STUDY TO COMPARE DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (DVRD) FOLLOWED BY CILTACABTAGENE AUTOLEUKEL VERSUS DARATUMUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (DVRD) FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE SUITABLE FOR TRANSPLANTATION. IMMUNOTHERAPY
- Code EudraCT: 2021-003284-10
- Protocol number: EMN28/68284528MMY300
- Promoter: European Myeloma Network (EMN)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.